Profile: David Michaels
December 27, 2012 | Video
A Robert Wood Johnson Health Policy Fellow describes how his experience in the program has been transformational, in more ways than one.
Government, Policy and Legal Issues
You are now viewing 1 - 10 of 61 results
Sort results by:
False Claims Act Prosecution Did Not Deter Off-Label Drug Use in the Case of Neurontin
December 1, 2011 | Journal Article
Since 2004 the United States has collected approximately $8 billion from fraud enforcement actions against pharmaceutical manufacturers accused under the federal False Claims Act of illegally promoting drugs for off-label uses.
Health Issues on Ballots Across the Country
November 9, 2012 | Human Capital Blog Post
Voters across the country were presented Tuesday with more than 170 ballot initiatives, many on health-related issues.
Rethinking the Obesity Epidemic
May 2, 2013 | Story
Abigail Saguy, PhD, a Scholar in RWJF's Scholar in Health Policy Research program, 2000-02, challenges assumptions regarding the health consequences of obesity and stereotypes about fat people.
Origins of Medical Innovation
November 1, 2012 | Journal Article
Individual inventors and scientists involved in the early stages of medical technology development play an important role in medical innovation.
Robert Wood Johnson Foundation Health Policy Fellows
February 16, 2012 | Program Result Report
The RWJF Health Policy Fellows Program awards six fellowships per year to mid-career health professionals and behavioral and social scientists with an interest in health to take part in the health policy process at the federal level.
Secondary Patenting of Branded Pharmaceuticals
October 10, 2012 | Journal Article
This article examines how secondary patents can extend market exclusivity and thus delay generic competition.
The Food and Drug Administration Has The Legal Basis to Restrict Promotion of Flawed Comparative Effectiveness Research
October 8, 2012 | Journal Article
Under FDA policy, communications by prescription drug manufacturers must be backed by “substantial evidence” from “adequate and well-controlled investigations.” But numerous exceptions permit manufacturer promotion based on data other than randomized trials.
User Fees and Beyond
October 4, 2012 | Journal Article
This perspective examines the Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) of 2012.
Statistical Security for Social Security
August 1, 2012 | Journal Article
The financial health of the U.S. Social Security program, which includes benefits for elderly and disabled persons, is an ongoing hot political, social, economic and policy issue. The Social Security Administration (SSA) evaluates various social, bi ...